· Published by Health Canada · Official notice
This is duplicated text of a letter from Celgene Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 26, 2013
Dear RevAid® Registered Prescriber, RevAid® Registered Pharmacist, or Allied Healthcare Professional:
Subject: Association of THALOMID® (thalidomide capsules) with arterial thromboembolic events
Celgene Inc., in consultation with Health Canada, would like to inform you of important new safety information regarding arterial thromboembolic events which have been added to the Product Monograph for THALOMID® (thalidomide capsules).
THALOMID® is an immunomodulatory agent indicated for the treatment of patients who are 65 years of age or older with previously untreated multiple myeloma, in combination with melphalan and prednisone.
The following points summarize the updated Product Monograph safety information:
The THALOMID® Canadian Product Monograph has been revised to include the updated risk information specific to arterial thromboembolic events within the Warnings and Precautions and Adverse Reactions sections as well as the Consumer Information section. This new information is in addition to information regarding the established risk of venous thromboembolic events, which was already reflected in the THALOMID® Product Monograph.
A copy of the most up-to-date THALOMID® Product Monograph can be found on the Health Canada Web site.
Distribution restrictions: THALOMID® is only available through a controlled distribution program called RevAid®. Under this program, only prescribers and pharmacists registered with the program are able to prescribe and dispense the product. In addition, THALOMID® can only be dispensed to patients who are registered and agree to the requirements of the RevAid® program. For more information, please log onto www.RevAid.ca.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of arterial thromboembolism or other serious or unexpected adverse reactions in patients receiving THALOMID® should be reported to Celgene Inc. or Health Canada.
Suspected adverse reactions can be reported to:
Celgene Inc.,
6755 Mississauga Road, Suite 600, Mississauga, ON, L5N 7Y2
Telephone: 1-877-923-5436
Facsimile: 1-289-291-4820
Email: drugsafety-canada@celgene.com
To correct your mailing address or fax number, contact Celgene Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions about THALOMID® or the RevAid® controlled distribution program, please call 1-888-RevAid1 (1-888-738-2431) or visit www.RevAid.ca
Sincerely,
original signed by
Dianne Azzarello, B.Sc.Phm.
Senior Director, Pharmacovigilance & Regulatory Affairs
THALOMID® and RevAid® are registered trademarks of Celgene Corporation.